Actinium, Columbia University to study Actimab-A in AML patients

Actinium Pharmaceuticals has entered into a research collaboration with Columbia University to study Actimab-A, its clinical-stage CD33 targeting radiotherapeutic, with engineered hematopoietic stem cells – eHSCs – modified by CRISPR/Cas9 gene editing technology to knock out CD33 expression. Under this collaboration, Actimab-A will be administered following transplantation of the eHSCs with the goal of eliminating any CD33 positive residual AML cells. This would allow a patient to receive CD33 targeting therapy post-transplant to eradicate any residual CD33 positive leukemia cells and prevent relapse while sparing newly formed blood cells that do not express CD33. Actimab-A has been studied in over 150 AML patients in six clinical trials. Recently, Actimab-A demonstrated high rates MRD negativity resulting in a 53% 1-year overall survival and 32% 2-year overall survival in a patient group that has an expected overall survival of less than 3 months.